Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Definium Therapeutics (NASDAQ:DFTX) had its price target boosted by equities researchers at Royal Bank Of Canada from $20.00 to $36.00 in a report issued on Friday, Marketbeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 106.90% from the company’s previous close.

A number of other brokerages have also recently issued reports on DFTX. Chardan Capital raised Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Lifesci Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th. Canaccord Genuity Group lifted their price objective on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Needham & Company LLC reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Finally, Jones Trading started coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Definium Therapeutics has an average rating of “Buy” and an average price target of $32.11.

Definium Therapeutics Trading Up 2.5%

Shares of Definium Therapeutics stock opened at $17.40 on Friday. The firm’s 50 day moving average is $13.16 and its 200 day moving average is $11.45. The firm has a market capitalization of $1.71 billion, a PE ratio of -8.53 and a beta of 2.57. Definium Therapeutics has a 1 year low of $4.70 and a 1 year high of $18.12. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). Equities research analysts forecast that Definium Therapeutics will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Definium Therapeutics news, insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the transaction, the insider owned 425,025 shares in the company, valued at $5,589,078.75. This trade represents a 1.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 42,667 shares of company stock valued at $561,071. Corporate insiders own 2.26% of the company’s stock.

Institutional Trading of Definium Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Palumbo Wealth Management LLC lifted its stake in Definium Therapeutics by 18.4% in the 4th quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after purchasing an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Definium Therapeutics in the fourth quarter worth $117,000. Bay Rivers Group increased its holdings in shares of Definium Therapeutics by 14.3% in the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after purchasing an additional 2,000 shares during the period. FNY Investment Advisers LLC purchased a new stake in shares of Definium Therapeutics in the third quarter worth $107,000. Finally, Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics in the third quarter worth $126,000. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.